This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.
CONMED (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Despite weak segmental performance in fourth quarter, CONMED (CNMD) showed strength and resilience in amid a tough operating environment.
Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in first-quarter fiscal 2021, driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Wall Street Selloff Makes Good Entry Point: 5 Stocks to Grab
by Nalak Das
At this stage, it will be prudent to invest in large-cap stocks that have strong growth potential for 2021. These are: FDX, F, HOLX, MOS and LEN.
Hologic (HOLX) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 33.64% and 0.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.
HOLX or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Top Ranked Growth Stocks to Buy for January 27th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 27th
QIAGEN (QGEN) Announces COVID-19 Test Updates as Cases Rise
by Zacks Equity Research
QIAGEN (QGEN) along with with Australia-based digital diagnostics company, Ellume develops QIAreach SARS-CoV-2 Antigen Test.
Hologic's (HOLX) CE-Marked Fluent System Launched in Europe
by Zacks Equity Research
Hologic (HOLX) aims to optimize, simplify and streamline hysteroscopic workflow with the latest European launch of its fluid management system.
Intuitive Surgical (ISRG) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter results reflect improvement in procedure volume.
Can Diagnostics Aid Hologic (HOLX) Q1 Sales Amid Coronavirus?
by Zacks Equity Research
Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the first quarter of fiscal 2021 amid the coronavirus-led economic doldrums.
Top Ranked Growth Stocks to Buy for January 21st
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 21st
6 Stocks Trading Near 52-Week Highs That Can Rally Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run, lately. Stocks seeing price strength have higher chances of carrying the momentum ahead.
Hologic (HOLX) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $77.22, marking a +1.62% move from the previous day.
Why You Should Retain Pacific Biosciences (PACB) Stock Now
by Zacks Equity Research
Investor confidence is high on Pacific Biosciences (PACB) stock, courtesy of solid prospects.
Masimo's (MASI) iSirona to Boost Hospital Automation Platform
by Zacks Equity Research
Masimo's (MASI) iSirona helps in efficient workflow in hospitals by providing continuous connectivity, thereby helping clinicians to improve patient outcomes.
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
by Sriparna Ghosal
Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
Want More Returns? Invest in Stocks With Momentum Anomaly
by Zacks Equity Research
Hologic (HOLX), SolarEdge Technologies (SEDG) and XPO Logistics (XPO) are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Becton, Dickinson and Co, Quidel and Hologic
Federal, Private Tie-Ups Boost COVID-19 Testing Volume
by Urmimala Biswas
The Department of Health and Human Services (HHS) promises over $22 billion of funding.
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Hologic (HOLX) due to a slew of regulatory approvals and buyouts.
Omnicell (OMCL) Reports Encouraging 2020 Preliminary Results
by Zacks Equity Research
Per the preliminary announcement, Omnicell (OMCL) projects 2020 total revenues to surpass its previous guidance.
Cardiovascular Systems' (CSII) OAS Gets CE Mark for Use in Europe
by Zacks Equity Research
Cardiovascular Systems (CSII) aims to expand treatment options in Europe for patients suffering from severely calcified coronary artery disease following the receipt of regulatory clearance.
Haemonetics (HAE) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Haemonetics (HAE) is optimistic about maintaining a robust product portfolio amid the pandemic-led business disruptions.